Generation of monocyte-derived dendritic cells from patients with renal cell cancer: Modulation of their functional properties after therapy with biological response modifiers (IFN-α plus IL-2 and IL-12)

Journal of Immunotherapy

Volumn 23, Issue 3, 2000, Pages 369-378

  Merad, Myriam ^a   Angevin, Eric ^a   Wolfers, Joseph ^a   Flament, Caroline ^a   Lorenzi, Isabelle ^a   Triebel, Frédéric ^a   Escudier, Bernard ^a   Zitvogel, Laurence ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Anti tumor Immunity; Immunomonitoring; Immunotherapy

Indexed keywords

ALPHA INTERFERON; BIOLOGICAL RESPONSE MODIFIER; INTERLEUKIN 12; INTERLEUKIN 2;

AGED; ALLOIMMUNITY; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; FLOW CYTOMETRY; HUMAN; IMMUNE RESPONSE; KIDNEY CARCINOMA; METASTASIS; PRIORITY JOURNAL; TUMOR IMMUNITY;

ANTIBODIES, MONOCLONAL; BIOLOGICAL RESPONSE MODIFIERS; CARCINOMA, RENAL CELL; CYTOKINES; DENDRITIC CELLS; DRUG THERAPY, COMBINATION; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-12; INTERLEUKIN-2; INTERLEUKIN-4; KIDNEY NEOPLASMS; LYMPHOCYTE CULTURE TEST, MIXED; MELANOMA; MONOCYTES; NEOPLASM METASTASIS; PEPTIDES; RECOMBINANT PROTEINS; T-LYMPHOCYTES; TETANUS TOXOID;

EID: 0034116322     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200005000-00010     Document Type: Article

References (43)

1. Rosenberg SA, Schwartz SL, Spiess PJ. Combination immunotherapy for cancer: synergistic antitumor interactions of interleukine-2, alpha interferon, and tumor-infiltrating lymphocytes. J Natl Cancer Inst 1988;80:1393-7.
2. Sparano JA, Fisher RI, Sunderland M. Randomized phase III trial of treatment with high dose interleukine-2 either alone or in combination with IFN alpha-2a in patients with advanced melanoma. J Clin Oncol 1993;11:1969-77.
3. Keilhoz U, Scheibenbogen C, Tilgen W. Interferon alpha and interleukine-2 in the treatment of metastatic melanoma. Cancer 1993;72:607-14.
4. Bergmann L, Fenchel K, Weidmann E. Daily alterning administration of higher dose alpha-2b IFN and IL-2 bolus infusion in metastatic renal cell cancer. A phase II study. Cancer 1993;72: 1733-42.
5. Palmer PA, Atzpodien J, Philip T. A comparison of 2 modes of administration of recombinant IL-2: continuous intraveinous infusion alone versus subcutaneous administration plus IFN alpha in patients with advanced renal cell carcinoma. Cancer Biother 1993; 8:123-36.
6. Negrier S, Escudier B, Lasset C, et al. Interleukine 2, interferon or both in 425 patients with metastatic renal cell carcinoma: results of a multicenter randomized trial. N Engl J Med 1998;18:1272-8.
7. Atkins MB, Robertson MJ, Gordon M, et al. Phase I evaluation of intravenous recombinant human interleukine 12 in patients with advanced malignancies. Clin Cancer Res 1997;3:409-17.
8. Trinchieri G. IL-12: a pro-inflammatory cytokine with immuno-regulatory functions that bridges innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995;13:251-76.
9. Bajetta E, Del Vecchio M, Mortarini R, et al. Pilot study of subcutaneous recombinant human interleukine 12 in metastatic melanoma. Clin Cancer Res 1998;4:74-85.
10. Budd GT, Osgood B, Barna B. Phase I clinical trial of IL-2 and IFN alpha: toxicity and immunologic effects. Cancer Res 1989; 49:6432-6.
11. Rubin JT, Elwood LJ, Rosenberg SA, Lotze MT. Immunohistochemical correlates of response to recombinant IL-2 based immunotherapy in humans. Cancer Res 1989;49:7086-92.
12. Pichert G, Jost LM, Fierz W, Stahel RA. Clinical and immune modulatory effects of alternative weekly IL-2 and IFN alpha-2a in patients with advanced renal cell cancer carcinoma and melanoma. Br J Cancer 1991;63:287-92.
13. Farace F, Pallardy M, Angevin E, et al. Metastatic renal cell carcinoma patients treated with interleukine 2 or interleukine 2 + interferon gamma; immunological monitoring. Int J Cancer 1994; 57:814-21.
14. Bukowski RM, Murthy S, Sergi JS. Phase I trial of continuous infusion recombinant interleukine-2 and intermittent recombinant interferon-alpha 2a: toxicity and immunologic effects. J Biol Resp Mod 1990;9:538-45.
15. Alexander JP, Kudoh S, Melsop KA. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce IL-2 and express IL-2 receptors. Cancer Res 1993; 53:1380-7.
16. Steinman R. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991;9:271-96.
17. Caux C, Massacrier C, Dezutter-Dambuyant C, et al. Human dendritic Langherans cells generated in vitro from CD34+ progenitors can prime naive CD4+ T cells and process soluble antigen. J Immunol 1995;155:5427-35.
18. Thurnher M, Radmayr C, Ramoner R, et al. Human Renal-Cell carcinoma tissue contains dendritics cells. Int J Cancer 1996;67: 1-7.
19. Enk AH, Jonuleit H, Saloga J, Knop J. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer 1997;73:309-16.
20. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52-8.
21. Tjoa BA, Erickson SJ, Bowes VA, et al. Follow up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides. Prostate 1997;32:272-8.
22. Nestle OF, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-32.
23. Radmayr C, Bock G, Hobish A, et al. Dendritic antigen-presenting cells from the peripheral blood of renal-cell-carcinoma patients. Int J Cancer 1995;63:627-32.
24. Espinoza-Delgado I, Rottschaffre S, Garcia CS, Curiel R. IL-2 activated human monocytes display an enhanced expression of B7.1 and recognition molecules. In: Steinman R, Nussenzweig M, and Banchereau J, eds. Cellular and Molecular Biology of Dendritic Cells: Keystone Symposia Meeting. Santa Fe, NM, 1998, p 46.
25. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J Exp Med 1994;179: 1109-18.
26. Dufour E, Carcelain G, Gaudin C, et al. Diversity of the cytotoxic melanoma-specific immune response: some CTL clones recognize autologous fresh tumor cells and not tumor cell lines. J Immunol 1997;158:3787-95.
27. Escudier B, Douillard JY, Chevreau C, et al. Is it useful to switch to IL-2 or IFN when progressive disease occurs after a first treatment with one of these cytokines? In: Perry MC, ed. Proceedings of the American Society of Clinical Oncologists. Philadelphia: WB Saunders, 1997, p 318.
28. Paquette RL, Hsu NC, Kiertscher SM, et al. IFNα and GM-CSF differentiate peripheral blood monocytes into potent antigen presenting cells. In: Steinman R, Nussenzweig M, and Banchereau J, eds. Cellular and Molecular Biology of Dendritic Cells: Keystone Symposia Meeting. Santa Fe, NM: 1998, p 53.
29. McRae BL, Semnani RT, Hayes MP, Van-Seventer GA. Role for type 1 IFN in human dendritic cell maturation and differentiation of Th1 cells. In: Steinman R, Nussenzweig M, and Banchereau J, eds. Cellular and Molecular Biology of Dendritic Cells: Keystone Symposia Meeting. Santa Fe, NM: 1998, p 94.
30. Hennemann B, Beckmann G, Eichelmann A, Rehm A Andreesen R. Phase I trial of adoptive immunotherapy of cancer patients using monocyte-derived macrophages activated with interferon gamma and lipopolysaccharide. Cancer Immunol Immunother 1998;45:250-6.
31. Jasani B, Navabi H, Adams M, Evans A, Mason M. Serum dependent downregulation of CD1a expression and specific CTL priming activity of human dendritic cells. In: Arnold PR, ed. Proceedings of AACR. New Orleans, LA: M Foti, 1998, p 611.
32. Macatonia SE, Hosken NA, Litton M, et al. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J Immunol 1995;154:5071-9.
33. Zitvogel L, Couderc B, Mayordomo JI, et al. IL-12 engineered dendritic cells serve as effective tumor vaccine adjuvants in vivo. Ann N Y Acad Sci 1996;795:284-93.
34. Schuler G, Steinman RM. Murine epidermal Langherans cells mature into potent immunostimulatory dendritic cells in vitro. J Exp Med 1985;161:526-46.
35. Schneekloth C, Korfer A, Hadam M, et al. Low-dose IL-2 in combination with IFN alpha effectively modulates biological response in vivo. Acta Haematol 1993;89:13-21.
36. Buzaid AC, Grimm EA, Ali-Osman F, et al. Mechanism of the anti-tumour effect of biochemotherapy in melanoma: preliminary results. Melanoma Res 1994;4:327-30.
37. Joffe JK, Banks RE, Forbes MA, et al. A phase II study of IFN alpha, IL-2 and 5-Fluorouracil in advanced renal cell carcinoma: clinical data and laboratory evidence of protease activation. Br J Urol 1996;77:638-49.
38. Ménétrier-Caux C, Caux C, Dieu MC, et al. IL-6 and M-CSF mediated inhibition of dendritic cell differentiation by tumor cells. In: Steinman R, Nussenzweig M, and Banchereau J, eds. Cellular and Molecular Biology of Dendritic Cells: Keystone Symposia Meeting. Santa Fe, NM: 1998, p 52.
39. Angevin E, Kremer F, Gaudin C, Hercend T, Triebel F. Analysis of T-cell immune response in renal cell carcinoma: polarization to typel-like differentiation pattern, clonal T-cell expansion and tumor-specific cytotoxicity. Int J Cancer 1997;72:431-40.
40. Bender A, Sapp M, Schuler G, Steinman RM, Bhardwaj N. Improved methods for the generation of dendritic cells from non proliferating progenitors in human blood. J Immunol Methods 1996;196:121-35.
41. Romani N, Reider D, Heuer M, et al. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods 1996;196:137-51.
42. Siena S, Di Nicola M, Bregni M, et al. Massive Ex-vivo generation of functionnal dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy. Exp Hematol 1995;23:1463-71.
43. Neumann E, Engelsberg A, Decker J, et al. Heterogeneous expression of tumor-associated antigens RAGE-1, FRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell immunotherapies? Cancer Res 1998;58:4090-5.